[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352911-105":59,"doc-detail-352911-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pan-cancer-pre-treatment-ctdna-detection-using-a-highly-sensitive-tumor-informed-assay","Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay","","Circulating tumor DNA (ctDNA) supports cancer detection, monitoring, and assessment of treatment response. This study assesses pre-treatment ctDNA detection in a single-institution pan-cancer cohort using a highly sensitive tumor-informed assay. Samples from University Health Network across six study cohorts were analyzed for 273 patients with stage II–IV cancers across 16 tumor types. Harmonized methods reduced known influences on ctDNA detection and quantification. Pre-treatment ctDNA was detected in 83% (226/273); rates varied by cancer type and stage, with 100% detection in stage IV metastatic recurrent HGSOC and 54% in stage IV melanoma.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-pre-treatment-ctdna-detection-using-a-highly-sensitive-tumor-informed-assay/352911/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-pre-treatment-ctdna-detection-using-a-highly-sensitive-tumor-informed-assay/352911.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of this study?","Question",{"text":113,"@type":114},"The study evaluates pre-treatment ctDNA detection across a pan-cancer cohort using a highly sensitive tumor-informed assay.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients and tumor types were analyzed?",{"text":118,"@type":114},"A total of 273 patients with stage II–IV cancers spanning 16 tumor types were analyzed.",{"name":120,"@type":111,"acceptedAnswer":121},"What ctDNA detection rate was observed overall and how did it vary?",{"text":122,"@type":114},"Pre-treatment ctDNA was detected in 83% of participants (226/273). Detection rates varied by cancer type and stage, reaching 100% in stage IV metastatic recurrent HGSOC and 54% in stage IV melanoma.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352911,1790156500,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Article  \nPan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay †  \nScott Strum 1,2, Clodagh Murray 3, Sofia Genta 4, Enrique Sanz-Garcia 1, Albiruni Razak 1, Stephanie Lheureux 1, Christodoulos Pipinikas 3, Ben X. Wang 1, Amber Chevalier 3, Christopher G. Smith 3, Anna Spreafico 1, Lillian L. Siu 1, Mitchell Elliott 1 and David W. Cescon 1, *  \n1 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada  \n2 Department of Medical Oncology, Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada  \n3 NeoGenomics, Inc., Fort Myers, FL 33912, USA  \n4 Department of Oncology, Queen’s School of Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada  \n* Correspondence: [dave.cescon@uhn.ca](dave.cescon@uhn.ca)  \n† Presented at the ISLB 2024—6th Annual Congress of Liquid Biopsy, Denver, CO, USA, 23–25 November 2024 .  \nAbstract  \nCirculating tumor DNA (ctDNA) has many potential applications in the management of cancer, including detection, monitoring, and treatment response assessment. This study evaluates pre-treatment ctDNA detection in a single-institution pan-cancer cohort using a highly sensitive tumor-informed ctDNA assay. Participant samples were collected at the University Health Network across six study cohorts. A total of 273 patients with stage II-IV cancers spanning 16 tumor types were analyzed using a personalized tumor-informed assay (RaDaR® ) . Harmonized methods were employed to mitigate the impact of variables known to influence ctDNA detection and its quantification. Pre-treatment ctDNA was detected in 83% of participants (226/273) across all stages and cancer types. Detection rates varied by clinical characteristics, including cancer type and stage; ctDNA was detected in 100% of stage IV metastatic recurrent high-grade serous ovarian cancer (HGSOC) patients (n = 8/8) and 54% of stage IV melanoma patients (n = 6/11) . The median estimated variant allele fraction (eVAF) across all patients with a positive ctDNA result was 0.25%(range: 0.000029–37.7%), varied by tumor type and increased with cancer stage. A total of 11% of positive samples (24/226) had an eVAF of \u003C0.01% . This pan-cancer ctDNA analysis using a highly sensitive assay reveals high detection rates overall, including ~10% at low levels (\u003C0.01% eVAF), offering a reference for future clinical ctDNA applications and furthering our understanding of factors influencing ctDNA measurements.  \nAcademic Editor: Hisham Bahmad  \nReceived: 14 February 2026  \nRevised: 4 April 2026  \nAccepted: 21 April 2026  \nPublished: 29 April 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nKeywords: ctDNA; MRD; cancer; biomarkers  \n1. Introduction  \nCancer biomarkers have an important role in modern oncology care and research [1,2] . They hold established applications across a number of clinical contexts, including screening, diagnosis, prognostication, treatment selection, and monitoring. While blood-based tumor markers have a role in clinical management, they are limited in many cases by their sensitivity and/or specificity. An emerging class of blood-based biomarkers, which detect and measure circulating tumor DNA (ctDNA), may offer improved test characteristics and could improve the management of patients with both early-and advanced-stage cancers.  \nctDNA is a tumor-derived subset of cell-free DNA (cfDNA) found in the blood circulation. DNA from tumors can also be detected in other body fluids, including cerebrospinal fluid, saliva, and urine [3] . Clinically, detection rates and levels of ctDNA are associated with tumor burden [4,5], anatomic location of disease [6], and changes in response to treatments such as chemotherapy, targeted therapy, immunotherapy, radiat","cbCaiiXUrmMJE3Ul","https://ap.wps.com/l/cbCaiiXUrmMJE3Ul","pdf",921024,11,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Cancer biomarkers and ctDNA\n## Tumor-informed vs tumor-agnostic assays\n## Need for pan-cancer detection-rate understanding","[{\"question\":\"What is the main purpose of this study?\",\"answer\":\"The study evaluates pre-treatment ctDNA detection across a pan-cancer cohort using a highly sensitive tumor-informed assay.\"},{\"question\":\"How many patients and tumor types were analyzed?\",\"answer\":\"A total of 273 patients with stage II–IV cancers spanning 16 tumor types were analyzed.\"},{\"question\":\"What ctDNA detection rate was observed overall and how did it vary?\",\"answer\":\"Pre-treatment ctDNA was detected in 83% of participants (226/273). Detection rates varied by cancer type and stage, reaching 100% in stage IV metastatic recurrent HGSOC and 54% in stage IV melanoma.\"}]","Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay | PDF",1790101961,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83d969c8c20875324dab28e97247ccbd.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/871f2c8b0dacef7637091829de7385db.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4403874d72b31d8a11dbd91f95da5437.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13930e588e808c36e856d918f26bea28.webp",980,1385]